Garry Menzel

Dr. Garry Menzel is a global healthcare executive with extensive experience in biotechnology and finance. They served as Managing Director and Global Head of Biotechnology at Goldman Sachs from 1994 to 2004, and later held leadership positions, such as Chief Operating Officer at Regulus Therapeutics and President at TCR² Therapeutics Inc. They are currently a Board Director at Adaptimmune and Black Diamond Therapeutics, and an Operating Partner at GHO Capital Partners LLP. Dr. Menzel earned a Ph.D. in Biochemistry and Molecular Biology from the University of Cambridge and an MBA from Stanford University Graduate School of Business.